Dogwood Therapeutics, Inc. (DWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.27 Million) by net assets ($77.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dogwood Therapeutics, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Dogwood Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore DWTX operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Dogwood Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dogwood Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MINDs Lab Inc.
KQ:377480
|
-0.082x |
|
Meditera Tibbi Malzeme Sanayi ve Ticaret AS
IS:MEDTR
|
0.057x |
|
QTC Energy Public Company Limited
BK:QTC
|
-0.052x |
|
BP Plastics Holding Bhd
KLSE:5100
|
0.020x |
|
Petros Petropoulos AEBE
AT:PETRO
|
-0.050x |
|
Kronos Bio Inc
NASDAQ:KRON
|
-0.161x |
|
GCL Global Holdings Ltd Ordinary Shares
NASDAQ:GCL
|
-0.003x |
|
Ace Technologies Corp
KQ:088800
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Dogwood Therapeutics, Inc. from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see DWTX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $64.28 Million | $-8.79 Million | -0.137x | +89.31% |
| 2023-12-31 | $3.81 Million | $-4.87 Million | -1.279x | +18.26% |
| 2022-12-31 | $7.33 Million | $-11.47 Million | -1.565x | -44.67% |
| 2021-12-31 | $14.50 Million | $-15.69 Million | -1.082x | -731.66% |
| 2020-12-31 | $29.94 Million | $-3.90 Million | -0.130x | -130.73% |
| 2019-12-31 | $-4.94 Million | $-2.09 Million | 0.423x | -55.39% |
| 2018-12-31 | $-1.26 Million | $-1.20 Million | 0.949x | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more